pI: 6.4422 |
Length (AA): 374 |
MW (Da): 41662 |
Paralog Number:
0
Signal peptide: Y | GPI Anchor: | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Mid 40-60% percentile | Procyclic, Bloodstream Form. | Siegel TN |
Siegel TN | Genome-wide analysis of mRNA abundance in two life-cycle stages of Trypanosoma brucei and identification of splicing and polyadenylation sites. |
Ortholog group members (OG5_130954)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT1G07010 | shewenella-like protein phosphatase 1 |
Arabidopsis thaliana | AT1G18480 | shewenella-like protein phosphatase 2 |
Cryptosporidium hominis | Chro.80040 | hypothetical protein |
Cryptosporidium parvum | cgd8_290 | serine-threonine protein phosphatase |
Leishmania braziliensis | LbrM.29.0380 | hypothetical protein, conserved |
Leishmania braziliensis | LbrM.22.1390 | Serine-threonin protein phosphatase, putative |
Leishmania donovani | LdBPK_290450.1 | hypothetical protein, conserved |
Leishmania donovani | LdBPK_221340.1 | Serine-threonin protein phosphatase, putative |
Leishmania infantum | LinJ.29.0450 | hypothetical protein, conserved |
Leishmania infantum | LinJ.22.1340 | Serine-threonin protein phosphatase, putative |
Leishmania major | LmjF.29.0440 | hypothetical protein, conserved |
Leishmania major | LmjF.22.1490 | Serine-threonin protein phosphatase, putative |
Leishmania mexicana | LmxM.22.1490 | Serine-threonin protein phosphatase, putative |
Leishmania mexicana | LmxM.08_29.0440 | hypothetical protein, conserved |
Neospora caninum | NCLIV_009030 | Metallophosphoesterase, related |
Oryza sativa | 4348542 | Os10g0394100 |
Oryza sativa | 4350234 | Os11g0261900 |
Plasmodium berghei | PBANKA_1332400 | shewanella-like protein phosphatase 1 |
Plasmodium falciparum | PF3D7_1469200 | shewanella-like protein phosphatase 1, putative |
Plasmodium knowlesi | PKNH_1211800 | shewanella-like protein phosphatase 1, putative |
Plasmodium vivax | PVX_117005 | shewanella-like protein phosphatase 1, putative |
Plasmodium yoelii | PY03645 | Ser/Thr protein phosphatase, putative |
Trypanosoma brucei gambiense | Tbg972.6.460 | serine/threonine protein phosphatase, putative |
Trypanosoma brucei | Tb927.6.750 | kinetoplastid-specific phospho-protein phosphatase, putative |
Trypanosoma cruzi | TcCLB.511825.170 | serine/threonine protein phosphatase, putative |
Trypanosoma cruzi | TcCLB.508409.329 | hypothetical protein, conserved |
Trypanosoma cruzi | TcCLB.508075.14 | hypothetical protein, conserved |
Trypanosoma cruzi | TcCLB.508323.190 | serine/threonine protein phosphatase, putative |
Toxoplasma gondii | TGME49_254770 | Ser/Thr phosphatase family protein |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.6.750 this record | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.6.750 this record | Trypanosoma brucei | significant gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.6.750 this record | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.6.750 this record | Trypanosoma brucei | significant gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
TGME49_254770 | Toxoplasma gondii | Probably non-essential | sidik |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
Affected Entity | Phenotypic quality | Occurs in | Occurs at | Evidence | Observed in | Drugs/Inhibitors |
---|---|---|---|---|---|---|
cell proliferation (GO:0008283) | normal (PATO:0000461) | bloodstream stage trypomastigotes (PLO:0027) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | normal cell proliferation (no significant loss or gain of fitness) in bloodstream forms (stage 3 days). | References: | 21363968 | |
cell proliferation (GO:0008283) | increased (PATO:0000470) | bloodstream stage trypomastigotes (PLO:0027) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | increased cell proliferation (significant gain of fitness) in bloodstream forms (stage 6 days). | References: | 21363968 | |
cell proliferation (GO:0008283) | normal (PATO:0000461) | procyclic (PLO:0034) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | normal cell proliferation (no significant loss or gain of fitness) in procyclic forms . | References: | 21363968 | |
cell proliferation (GO:0008283) | increased (PATO:0000470) | procyclic (PLO:0034) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | increased cell proliferation (significant gain of fitness) in differentiation of procyclic to bloodstream forms . | References: | 21363968 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
1 literature reference was collected for this gene.